Ujvira 100mg Injection

MRP: ₹37495.31 Discount: 46%
Sale Price:

₹20300.00

Ujvira powder for injection contains trastuzumab emtansine, a prescription medication for treating HER2-positive breast cancer. This drug combines trastuzumab, an antibody targeting HER2 receptors, with emtansine, a chemotherapy agent that destroys cancer cells. Ujvira powder for injection is indicated for both early and advanced stages of breast cancer, particularly in cases where the disease recurs within six months following chemotherapy.

Add to Cart

Weight/Quantity: 1 VIAL

Store in a refrigerator (2 °C – 8 °C).

Ujvira 100mg Injection is a targeted therapy containing the active constituent trastuzumab emtansine. The U.S. Food and Drug Administration (FDA) approved trastuzumab emtansine on February 22, 2013, for treating patients with HER2-positive metastatic breast cancer who have previously received trastuzumab and chemotherapy. This medication is not recommended for adolescents and children under 18. Before taking this medicine, it is vital to inform your doctor if you have any blood clot disorders, liver disorders, or allergies.

Ujvira 100mg Injection is indicated for its use in the following conditions:
Advanced and metastatic breast cancer

1.Ujvira 100mg Injection shall either be administered before or after surgery.

2. It will be given as an Intravenous infusion for 90 minutes, if well tolerated it shall be administered within 30 minutes for the next doses.

Side effects are unwanted symptoms caused by medicines. Even though all medicines cause side effects, not everyone gets them.

Serious

Heart Problems
Allergic reactions
Kidney problems
Breathing difficulties